港股異動 | 先聲藥業(2096.HK)漲超5% 2款抗腫瘤創新藥獲批臨牀
格隆匯12月9日丨先聲藥業(2096.HK)拉昇漲超5%,現報9.55港元,總市值251億港元。日前公司兩款1類新藥已獲得臨牀試驗默示許可,分別是:自主研發的抗TNFR2抗體SIM0235(1811-03),擬用於治療晚期實體瘤和皮膚T細胞淋巴瘤;與KAZIA合作的PI3K/mTOR通路抑制劑SIM0395(paxalisib),擬用於新診斷和復發的膠質母細胞瘤。據悉,這是近期先聲藥業創新藥研發管線的又一重要進展。不久前,公司引進的CDK 4/6抑制劑剛在中國遞交新藥上市申請。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.